IART Integra Lifesciences Holdings Corp
Price (delayed)
$22.49
Market cap
$1.74B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.09
Enterprise value
$3.47B
Integra LifeSciences is a global leader in regenerative tissue technologies and neurosurgical solutions dedicated to limiting uncertainty for clinicians, so they can focus on providing the best patient care. Integra
Highlights
The revenue is up by 4.5% year-on-year and by 2.9% since the previous quarter
The gross profit is up by 2.6% since the previous quarter
IART's EPS has dropped by 111% year-on-year and by 13% since the previous quarter
Integra Lifesciences Holdings's net income has plunged by 110% YoY and by 6% from the previous quarter
Key stats
What are the main financial stats of IART
Market
Valuations
Earnings
Shares outstanding
77.22M
Market cap
$1.74B
Enterprise value
$3.47B
Price to earnings (P/E)
N/A
Price to book (P/B)
1.12
Price to sales (P/S)
1.08
EV/EBIT
66.32
EV/EBITDA
17.9
EV/Sales
2.16
Revenue
$1.61B
Gross profit
$882.06M
Operating income
$28.41M
Net income
-$6.94M
EBIT
$52.4M
EBITDA
$194.12M
Free cash flow
$24.96M
Per share
Balance sheet
Liquidity
EPS
-$0.09
EPS diluted
-$0.09
Free cash flow per share
$0.32
Book value per share
$20.03
Revenue per share
$20.91
TBVPS
$22.5
Total assets
$4.04B
Total liabilities
$2.49B
Debt
$1.98B
Equity
$1.55B
Working capital
$159.56M
Debt to equity
1.28
Current ratio
1.17
Quick ratio
0.59
Net debt/EBITDA
8.95
Margins
Efficiency
Dividend
EBITDA margin
12.1%
Gross margin
54.8%
Net margin
-0.4%
Operating margin
1.8%
Return on assets
-0.2%
Return on equity
-0.4%
Return on invested capital
1.8%
Return on capital employed
1.7%
Return on sales
3.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IART stock price
How has the Integra Lifesciences Holdings stock price performed over time
Intraday
-0.97%
1 week
0.63%
1 month
6.44%
1 year
-34.68%
YTD
-0.84%
QTD
-0.84%
Financial performance
How have Integra Lifesciences Holdings's revenue and profit performed over time
Revenue
$1.61B
Gross profit
$882.06M
Operating income
$28.41M
Net income
-$6.94M
Gross margin
54.8%
Net margin
-0.4%
Integra Lifesciences Holdings's net income has plunged by 110% YoY and by 6% from the previous quarter
The net margin has dropped by 109% year-on-year
IART's operating margin has dropped by 75% year-on-year
The operating income has dropped by 75% year-on-year
Growth
What is Integra Lifesciences Holdings's growth rate over time
Valuation
What is Integra Lifesciences Holdings stock price valuation
P/E
N/A
P/B
1.12
P/S
1.08
EV/EBIT
66.32
EV/EBITDA
17.9
EV/Sales
2.16
IART's EPS has dropped by 111% year-on-year and by 13% since the previous quarter
The P/B is 57% lower than the 5-year quarterly average of 2.6 and 14% lower than the last 4 quarters average of 1.3
The equity has declined by 2.7% year-on-year
The price to sales (P/S) is 60% less than the 5-year quarterly average of 2.7 and 17% less than the last 4 quarters average of 1.3
The revenue is up by 4.5% year-on-year and by 2.9% since the previous quarter
Efficiency
How efficient is Integra Lifesciences Holdings business performance
IART's ROA has shrunk by 111% YoY
Integra Lifesciences Holdings's return on equity has shrunk by 110% YoY
IART's return on invested capital has dropped by 64% year-on-year
IART's return on sales has dropped by 62% year-on-year and by 2.9% since the previous quarter
Dividends
What is IART's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IART.
Financial health
How did Integra Lifesciences Holdings financials performed over time
The company's total assets is 62% higher than its total liabilities
IART's quick ratio has plunged by 68% YoY
The current ratio has dropped by 66% year-on-year and by 2.5% since the previous quarter
The debt is 28% greater than the equity
Integra Lifesciences Holdings's debt to equity has increased by 21% YoY but it has decreased by 2.3% QoQ
The debt is up by 18% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.